AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

NCT05840016 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

532

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Squamous Non Small Cell Lung Cancer

Interventions

DRUG: AK112, Carboplatin, Paxlitaxel
DRUG: Tislelizumab, Carboplatin, Paxlitaxel

Sponsor

Akeso